New combo therapy trial offers hope for Tough-to-Treat blood cancer
NCT ID NCT06675123
Summary
This early-stage study is testing whether adding a drug called pacritinib to a standard BTK inhibitor treatment is safe and might work better for people with mantle cell lymphoma that has come back or hasn't responded to prior therapy. The trial will enroll about 10 patients to check for side effects and see if the combination can help control the cancer. Researchers hope blocking two different cancer growth pathways at once could be more effective.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT MANTLE CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91010, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.